Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms.

Zhi-peng HE; Hui-yun Tian; Ming Tan; Yong WU

Return

Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms.

Author: Zhi-Peng HE ¹ ; Hui-Yun TIAN ¹ ; Ming TAN ¹ ; Yong WU ²
Author Information

1. Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001,Fujian Province,China.
2. Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001,Fujian Province,China. E-mail: wuyong9195@126.com.
Publication Type:Journal Article
MeSH: Calreticulin; Humans; Janus Kinase 2; Mutation; Primary Myelofibrosis; Retrospective Studies; Thrombocythemia, Essential
From: Journal of Experimental Hematology 2018;26(3):842-848
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the relationship between driver mutations and clinical characteristics in patients with Philadelphia chromosome (Ph) negative myeloproliferative neoplasms (MPN), so as to provide evidence for diagno-sis and treatment of the disease.
METHODSThe clinical data of 410 patients with classic Ph negative MPN including 150 cases of polycythemia vera (PV), 188 cases of essential thrombocythemia (ET) and 72 cases of primary myelofibrosis (PMF) from January 2013 to December 2016 in Fujian Medical University Union Hospital were retrospectively analyzed. The PCR or DNA sequencing were used for JAK2 V617F, JAK2 exon12, CALR and MPL W515L/K mutation analyses, and follow-up information on patients was updated by direct phone call or follow-up in outpatient.
RESULTSAmong the 410 patients with Ph negative MPN, 136 (33.2%) cases were asymptomatic at diagnosis. 389 cases were sequenced and JAK2 V617F was detected in 87.1% (122/140) of PV, 64.1% (118/184) of ET, 64.6% (42/65) of PMF; JAK2 exon 12 mutation in 1 case of PV; MPL W515L/K mutation in 1 case of ET and PMF, respectively; CALR mutation in 18(9.8%) cases of ET and 5 (7.7%) cases of PMF. JAK2 V617F mutated PV patients ocourred in older age: the white blood cell count, platelet count and incidence of splenomegaly were higher than JAK2-negative PV cases(P<0.05). Compared with JAK2 V617F mutated ET patients, CALR mutated ET cases displayed younger age, lower leukocyte count, higher platelet count and lower incidence of thrombosis; JAK2-negative ET cases had younger age, lower leukocyte count, lower hemoglobin level, higher platelet count and lower incidence of thrombosis(P<0.05). The incidence of splenomegaly in JAK2 V617F or CALR mutated PMF patients was both higher than that in JAK2-negative PMF cases, but the incidence of leukemia transformation in JAK2-negative PMF patients was higher than that in JAK2 V617F mutated cases (P<0.05).
CONCLUSIONThe types of driver mutations are closely related with the clinical features and prognosis in Ph negative MPN patients.